8-K: Alphatec Holdings Reports Q3 2026 Results, Revenue Up 13%

Alphatec Holdings announced third quarter 2026 financial results, with total revenue reaching $221 million, a 13% increase year-over-year, driven by strong surgical revenue growth.

Summary

• Alphatec Holdings reported third quarter 2026 total revenue of $221 million, a 13% increase year-over-year.
• Surgical revenue grew 14% to $202 million, with hardware contributing $26 million to this growth.
• Case volumes increased by 20%, and net new surgeon users grew by 25%.
• GAAP gross margin was 71.5%, and non-GAAP gross margin was 71.9%.
• GAAP net loss was $5 million, while non-GAAP net income was $15 million.
• Non-GAAP adjusted EBITDA was $38 million, representing a 17.3% margin, an expansion of 400 basis points year-over-year.
• The company generated $6 million in free cash flow during the quarter.
• For the full year 2026, the company now expects total revenue of approximately $862 million and adjusted EBITDA of approximately $137 million.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report. While revenue and surgical growth are positive, the miss on total revenue expectations due to lower biologics attachment indicates areas for improvement.

Positives

• Total revenue increased by 13% year-over-year to $221 million.
• Surgical revenue showed strong growth of 14% to $202 million.
• Surgical hardware revenue increased by 17% year-over-year.
• Case volumes grew by approximately 20%.
• Net new surgeon users increased by 25%.
• Non-GAAP adjusted EBITDA margin expanded by 400 basis points year-over-year to 17.3%.
• Generated $6 million in free cash flow in the third quarter.
• Positive trailing twelve-month free cash flow was maintained.

Negatives

• Third-quarter revenue fell short of expectations, primarily due to lower biologics attachment.
• GAAP net loss for the quarter was $5 million.
• Full-year 2026 revenue outlook was revised to approximately $862 million, implying a slight adjustment from previous expectations.
• Full-year 2026 free cash flow expectation is approximately $10 million, which may be lower than some investors anticipate given the quarterly performance.

Risks

• Uncertainty of success in developing new products or products currently in the pipeline.
• Uncertainties in the Company's ability to execute upon its strategic operating plan.
• Uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products.
• Failure to achieve acceptance of the Company's products by the surgeon community.
• The Company's inability to improve biologics performance and product mix.
• Competitive pressures and market dynamics.
• Failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process.
• Unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability.

Future Outlook

For the full fiscal year 2026, Alphatec Holdings now expects total revenue of approximately $862 million, including approximately $789 million of surgical revenue and $73 million of EOS revenue. This represents approximately 13% total revenue growth and 15% surgical revenue growth for the year. The company anticipates adjusted EBITDA of approximately $137 million, reflecting continued year-over-year profitability expansion. Additionally, the company expects approximately $10 million of free cash flow for fiscal year 2026.

Management Comments

• "Third-quarter revenue fell short of our expectations, primarily due to lower biologics attachment," said Pat Miles, Chairman and Chief Executive Officer.
• "We own and are addressing that shortfall, and going forward, improving biologics performance is a clear priority for us."
• "At the same time, we continued to see very strong demand for our procedural solutions, with hardware revenue growing 17%, case volumes growing approximately 20%, and new surgeon adoption increasing 25%."
• "These results reinforce our confidence in our procedure-focused strategy and the clinical value of our ecosystem."
• "The disciplined execution of biologics is required to realize full procedural revenue translation, while building the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive)."
• "We remain bullish on our ability to make continued progress toward increasingly profitable growth."

Industry Context

StockSavvy.ai notes that Alphatec's performance in the spine surgery market is influenced by broader trends in medical device innovation, surgeon adoption of new technologies, and the increasing focus on integrated procedural solutions. The company's emphasis on hardware growth and surgeon user acquisition aligns with industry efforts to improve surgical outcomes and efficiency. However, the challenge with biologics attachment highlights a common complexity in the medical device sector, where multiple product components need to be adopted in conjunction for optimal revenue realization.

Management Changes

Legal Proceedings

• The company is involved in various litigation matters, with litigation-related expenses noted in financial statements.

Stakeholder Impact

• Shareholders: Potential impact from revenue miss on biologics, but offset by strong core growth and improved profitability metrics. Full-year guidance update provides clarity.
• Employees: Continued focus on strategic growth and innovation may lead to opportunities, but also potential restructuring impacts if operational improvements require it.
• Customers (Surgeons/Hospitals): Continued strong demand for procedural solutions and new surgeon adoption are positive. Biologics attachment issue may require further education or product adjustments.
• Suppliers: Stable demand for surgical hardware and components is likely. Biologics suppliers may face pressure if attachment rates do not improve.

Next Steps

• Focus on improving biologics performance as a clear priority.
• Continue to drive strong demand for procedural solutions.
• Realize full procedural revenue translation through disciplined execution of biologics.
• Build the foundation for the longer-term opportunity with OsteoAdapt (Theradaptive).
• Make continued progress toward increasingly profitable growth.

Key Dates

Recommendation

The report shows solid growth in core surgical revenue and improved profitability (EBITDA margin expansion), which are positive indicators. However, the explicit miss on total revenue expectations due to lower biologics attachment, coupled with a GAAP net loss, introduces a note of caution. While management is addressing the biologics issue, the uncertainty and the need for disciplined execution warrant a 'hold' rating until performance in this area improves and the full-year outlook is more confidently met.

Keywords

Spine Surgery, Medical Devices, Revenue Growth, EBITDA, Financial Results, Surgical Hardware, Biologics, Cash Flow